Repatha (Evolocumab) Global Regulatory Status
A comprehensive review of Repatha's FDA approval, EMA authorization, label expansions, FOURIER outcomes data, and current regulatory standing across major markets.
Read clinical reviewTopic Hub
Evolocumab — Regulatory History
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
5articles
35keywords mapped
2026-05-26latest review
Explore
Evolocumab — Regulatory History library
Showing 5 of 5 clinical reviews.
Repatha (Evolocumab) Pipeline, FDA History, and Next-Generation PCSK9 Therapies
A clinical review of Repatha's FDA approval history, current label indications, post-market safety data, and emerging next-generation PCSK9-targeting therapies in development.
Read clinical reviewRepatha (Evolocumab): EMA vs FDA Regulatory Approach
A detailed comparison of how the FDA and EMA have regulated Repatha (evolocumab), including approval timelines, label differences, post-market surveillance, and safety requirements.
Read clinical reviewRepatha (Evolocumab): Legal and Patent Challenges, FDA History, and Regulatory Field
A clinical review of Repatha's FDA approval history, patent disputes with Sanofi/Regeneron, label updates, post-market safety surveillance, and the regulatory path that shaped PCSK9 inhibitor access.
Read clinical reviewRepatha FDA Approval History: Every Label Change From 2015 to Today
A complete timeline of Repatha (evolocumab) FDA approvals, supplemental indications, boxed-warning updates, and post-market safety data from 2015 through 2026.
Read clinical review